NCT02101268 - Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF | Biotech Hunter

Enrollment

156

Participants

Timeline

Start Date

June 19, 2014

Primary Completion Date

July 28, 2016

Study Completion Date

April 25, 2019

Conditions

Primary Myelofibrosis (PMF)Post-polycythemia Vera (Post-PV)Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)

Interventions

DRUG

Momelotinib

Momelotinib tablet administered orally once daily

DRUG

Best Available Therapy (BAT)

Regimens for BAT may include but are not limited to chemotherapy (eg hydroxyurea), anagrelide, corticosteroid, hematopoietic growth factor, immunomodulating agent, androgen, interferon, and may include no myelofibrosis treatment.

Trial Locations (48)

Unknown

Los Angeles

Gainesville

Atlanta

Kansas City

Baltimore

St Louis

Albuquerque

New York

Durham

Winston-Salem

Cleveland

Pittsburgh

Houston

Edmonton

Montreal

Toronto

Lille

Marseille

Nantes

Paris

Pierre-Bénite

Toulouse

Villejuif

Cologne

Dresden

Hamburg

Mannheim

Ashkelon

Haifa

Jerusalem

Tel Aviv

Bologna

Florence

Genova

Milan

Novara

Roma

Varese

Badalona

Barcelona

Madrid

Salamanca

Valencia

Zaragoza

Birmingham

Leeds

Leicester

London

All Listed Sponsors

lead

Sierra Oncology LLC - a GSK company

INDUSTRY